Losartan for hypertension
Article Abstract:
Losartan (Cozaar) appears to effectively reduce high blood pressure while avoiding the bothersome side effects caused by similar classes of drugs. Losartan blocks the blood-pressure-raising action of a compound in blood vessels called angiotensin II. This oral medication is rapidly absorbed, reaching peak blood concentrations within one hour. Clinical trials indicate that losartan lowers blood pressure as effectively as an ACE inhibitor or a beta-blocker. People taking losartan have a low rate of side effects and may not experience the cough or swelling associated with ACE inhibitors. The typical dose of losartan ranges between 50 and 100 milligrams per day. Treatment-resistant patients may benefit from the addition of a diuretic to enhance the blood-pressure-lowering effect of losartan.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Valsartan for hypertension
Article Abstract:
The FDA has approved valsartan for the treatment of hypertension. The drug is marketed under the name Diovan and blocks the angiotensin II receptor. Because of this, it differs from most ACE inhibitors, which block the conversion of angiotensin I to angiotensin II. Clinical trials show it is as effective as Vasotec and Norvasc. Valsartan does not cause cough as many ACE inhibitors do.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Candesartan for hypertension
Article Abstract:
Candesartan cilexetil has been approved for the treatment of hypertension. Sold under the trade name Atacand, the drug is an angiotensin II receptor antagonist that provides the benefits of angiotensin-converting enzyme (ACE) inhibitors without causing a cough. Atacand is intended for patients who cannot tolerate ACE inhibitors for blood pressure control.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Bleeding complications with tension-free vaginal tape operation. Predicting uterine weight before hysterectomy: Ultrasound measurements versus clinical assessment
- Abstracts: Capitation or decapitation: keeping your head in changing times. Effectiveness of University of California postbaccalaureate premedical programs in increasing medical school matriculation for minority and disadvantaged students
- Abstracts: Reperfusion for right ventricular infarction. Thrombus aspiration during primary percutaneous coronary intervention
- Abstracts: Metformin for non-insulin-dependent diabetes mellitus. Glyburide/metformin (Glucovance) for type 2 diabetes. Troglitazone for non-insulin-dependent diabetes mellitus
- Abstracts: Target 2000. Polio eradication is in sight. Measles in the cities